Sex: U
Vaccine: COVID19
Symptoms: Myalgia, Nausea, Pyrexia, Vaccination site erythema, Vaccination site pain
Clinical narrative: Moderate malaise/feeling sick present with some interference with activity ; Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement) ; Mild injection site redness; Mild injection site swelling; Moderate fever (101.3 to 102 °F); Mild fatigue and no interference with activity; Moderate muscle pain with some interference with activity ; Joint pain with some interference with activity ; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Headache and no interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Moderate malaise/feeling sick present with some interference with activity ), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement) ), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling) and PYREXIA (Moderate fever (101.3 to 102 °F)) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Moderate malaise/feeling sick present with some interference with activity ), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement) ), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), PYREXIA (Moderate fever (101.3 to 102 °F)), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Moderate muscle pain with some interference with activity ), ARTHRALGIA (Joint pain with some interference with activity ), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and HEADACHE (Headache and no interference with activity). At the time of the report, MALAISE (Moderate malaise/feeling sick present with some interference with activity ), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement) ), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), PYREXIA (Moderate fever (101.3 to 102 °F)), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Moderate muscle pain with some interference with activity ), ARTHRALGIA (Joint pain with some interference with activity ), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and HEADACHE (Headache and no interference with activity) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: Moderate fever (101.3 to 102 Degree F).     The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       The Subject ID was reported. The Subject ID was reported. Concomitant medication was not reported. Patient had experienced injection site pain, injection site tenderness, injection site redness, injection site swelling, fever, fatigue, malaise/feeling sick, nausea, vomiting, joint pain and headache anytime during the 2 days after your COVID-19 vaccination, which occurred on Wednesday, 20-Dec-2023 and Thursday, 21-Dec-2023.  Treatment medication was not reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099: